MS

MS Society protests NICE rejection of Ocrevus for primary progressive MS
BioCentury
Mon, 09/10/18 - 12:16 am
NICE
UK
MS
multiple sclerosis
Ocrevus
ocrelizumab
Roche
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst
Fierce Pharma
Fri, 08/31/18 - 11:44 pm
Biogen
Teva Pharmaceutical
MS
multiple sclerosis
payers
Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review
The Pharma Letter
Wed, 08/1/18 - 10:43 am
Merck KGaA
Mavenclad
cladribine
MS
multiple sclerosis
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Wed, 07/18/18 - 10:49 pm
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Will Mylan’s big Copaxone price break force Teva’s hand? Clients are pushing already
Fierce Pharma
Mon, 07/16/18 - 11:29 am
Mylan Labs
Copaxone
generics
Teva Pharmaceuticals
MS
drug pricing
MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too
Fierce Pharma
Fri, 07/13/18 - 11:52 am
patents
Novartis
MS
Gilenya
Celgene
exclusivity
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study
Fierce Pharma
Wed, 06/6/18 - 09:32 pm
Roche
MS
multiple sclerosis
Ocrevus
FDA
vaccines
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Sat, 05/5/18 - 10:58 am
Celgene
ozanimod
MS
multiple sclerosis
FDA
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Sat, 04/28/18 - 11:53 am
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Tue, 04/24/18 - 10:31 am
Celgene
ozanimod
relapsing multiple sclerosis
MS
Lemtrada Treatment Effects in MS Patients Maintained Over Seven Years
CP Wire
Tue, 04/24/18 - 09:02 am
Sanofi Genzyme
Lemtrada
MS
Relapsing Remitting Multiple Sclerosis
Novartis pads case for new MS blockbuster with disease-progression analysis
Fierce Pharma
Sat, 04/21/18 - 12:41 pm
Novartis
MS
multiple sclerois
siponimod
Mylan and Mapi Pharma Partner on Once Monthly Glatiramer Acetate Drug for Relapsing-Remitting MS
CP Wire
Tue, 04/10/18 - 11:24 am
Mylan Labs
Mapi Pharma
GA Depot
MS
Relapsing Remitting Multiple Sclerosis
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Wed, 04/4/18 - 08:52 am
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
CP Wire
Fri, 03/23/18 - 12:55 am
Novartis
siponimod
clinical trials
MS
multiple sclerosis
SPMS
Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
Endpoints
Fri, 03/2/18 - 11:08 am
Biogen
AbbVie
MS
multiple sclerosis
Zinbryta
Europe
encephalitis
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Tue, 02/27/18 - 06:47 pm
Celgene
FDA
MS
multiple sclerosis
ozanimod
Celgene's Future Growth Could Depend on a Competitor's Trial This Quarter
Motley Fool
Wed, 02/14/18 - 11:20 am
Celgene
etrasimod
ozanimod
Arena Pharmaceuticals
MS
multiple sclerois
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
Endpoints
Tue, 02/13/18 - 09:11 am
Novartis
Momenta Pharmaceuticals
FDA
Copaxone
Teva Pharmaceutical
Glatopa
MS
multiple sclerosis
Will Teva Pharmaceutical's Pain Be Mylan's Gain?
Motley Fool
Fri, 02/9/18 - 09:33 am
Teva Pharmaceutical
Mylan Labs
Copaxone
generics
MS
multiple sclerosis

Pages